Kodu・Aktsiate loetelu・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Avatud

SektorTervishoid

2.48 2.06

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.38

Max

2.48

Põhinäitajad
By Trading Economics
Sissetulek	171M 123M
Aktsiakasum	-0.15
Töötajad	202
EBITDA	179M 134M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+289.34% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	4. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-147M 250M
Eelmine avamishind	0.42
Eelmine sulgemishind	2.48

Rocket Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. okt 2026, 19:53 UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

29. okt 2026, 20:07 UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

28. okt 2026, 22:21 UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

27. okt 2026, 20:01 UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

26. okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

23. okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22. okt 2026, 20:07 UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

21. okt 2026, 22:21 UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

20. okt 2026, 20:21 UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

19. okt 2026, 20:07 UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

16. okt 2026, 21:01 UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

15. okt 2026, 20:02 UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

13. okt 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

12. okt 2026, 20:06 UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

9. okt 2026, 21:10 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

8. okt 2026, 23:10 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

7. okt 2026, 20:07 UTC

Social Media

News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

6. okt 2026, 22:01 UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

5. okt 2026, 20:06 UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2. okt 2026, 19:45 UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

1. okt 2026, 21:01 UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

30. sept 2026, 20:07 UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

29. sept 2026, 23:01 UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

28. sept 2026, 23:26 UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

25. sept 2026, 23:56 UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

24. sept 2026, 20:01 UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

23. sept 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

22. sept 2026, 23:21 UTC

Rocket Pharmaceuticals Inc is seeing a modest increase in after-market trading, building on Tuesday's close, although it remains below its 20-day moving average.

21. sept 2026, 22:06 UTC

Advanced modestly in after-market trading despite economic growth concerns.

18. sept 2026, 22:56 UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, maintaining an upward trend since Friday's close despite being below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Rocket Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

289.34% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD 289.34%

Kõrge 15 USD

Madal 4 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Rocket Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Rocket Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.